To study the clinical efficacy and safety of autologous umbilical cord blood transfusion in the treatment of autism spectrum disorder.

This is a Phase 1 clinical trial that constitutes two time points cohorts with participants who will receive intravenous autologous umbilical cord blood and 0.9% sodium chloride respectively. The timing of treatment is any time after the diagnosis of autism spectrum disorder. The investigator will proceed the groups during the same period.

1. Demographic Data and Baseline Characteristics of the Studied Group were collected:

   • Basic patient's information survey
   • Medical history
   • Physical examination
   • Basic blood test result
   • Autism Behavior Checklist,CARS before the treatment
   • Brain Magnetic Resonance Imaging-Diffusion Tensor Imaging (MRIDTI) before the treatment
   • Neurocognitive function test before the treatment

2. Assessment of clinical condition in the course by measurement of blood pressure, heart and respiratory rates, temperature and adverse events was recorded.

3. Autologous cord blood doses is 20-30ml (total Mononuclear cells# 1*10^7/kg)#the infusion speed is 1ml/min, and with same volume of 0.9% sodium chloride as placebo.

4. The follow-up: clinical test until 24th month in 3 month gaps.

Inclusion Criteria:

• • A patient who was diagnosed with ASD.

Exclusion Criteria:

• • In case a patient underwent a surgical procedure, or was administered autologous cord blood within one year before participating in a clinical trial.

  • Accompanied by a serious disease, such as chromosome abnormality, etc.
  • In case where a patient's medical condition is judged to be maladapted by a researcher.
  • In case a patient or his or her legal representative doesn't agree to participation in a clinical trial.
  • A patient having a predisposition to allergies.
  • A patient having serious disorders in the liver, kidney, and cardiopulmonary function.